September 11, 2012
Pfizer Inc. (US) announced that it obtained marketing authorization from the European Commission (EC) on September 3 local time for the anticancer agent Inlyta (axitinib) for treating advanced renal cell carcinoma (RCC) in adults after failure of previous treatments with...read more